Allocation to an SGLT2 inhibitor reduced the risk of cardiovascular death by 14% (0·86, 0·81–0·92), again with similar effects observed in those with diabetes (0·86, 0·80–0·92) and those without diabetes (0·88, 0·78–1·01; heterogeneity p=0·68). This evidence concerns the gene SLC5A2 and diabetes mellitus.